CAW
RIGL icon

Cornerstone Advisors (Washington)’s Rigel Pharmaceuticals RIGL Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-119
Closed -$4K – 925
2015
Q4 		$4K Hold
119
– – ﹤0.01% 614
2015
Q3 		$3K Hold
119
– – ﹤0.01% 661
2015
Q2 		$4K Hold
119
– – ﹤0.01% 463
2015
Q1 		$4K Hold
119
– – ﹤0.01% 482
2014
Q4 		$3K Sell
119
-118
-50% -$2.39K ﹤0.01% 506
2014
Q3 		$5K Hold
237
– – ﹤0.01% 272
2014
Q2 		$9K Buy
+237
New +$8.06K 0.01% 229

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cornerstone Advisors (Washington)'s RIGL Position: Q1 2016 in Review

Cornerstone Advisors (Washington) sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 119 shares — an estimated $4K sold.

Cornerstone Advisors (Washington) first reported a position in RIGL in Q2 2014 and held it in 7 quarters. The position peaked at $9K in Q2 2014. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

  • Cornerstone Advisors (Washington) reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 119 Rigel Pharmaceuticals shares in Q1 2016, an estimated $4K.
  • Cornerstone Advisors (Washington) first reported a position in Rigel Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • Cornerstone Advisors (Washington)'s Rigel Pharmaceuticals position peaked at $9K in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q1 2016, filed 20 Apr 2016.